|
End-of-day quote
Dhaka S.E.
15/10/2026
|
5-day change | 1st Jan Change | ||
| 145.80 BDT | +0.62% |
|
+0.83% | +42.80% |
| 10-01 | Beximco Pharmaceuticals Reaches Settlement With Bangladeshi Regulator Over Board Restructuring | MT |
| 09-30 | Beximco Pharmaceuticals PLC Announces Iqbal Ahmed to Step Down from Managing Director | CI |
| Market Cap | 65.04B 526M 468M 434M 395M 745M 49.99B 758M 5.21B 2.05B 26.06B 1.98B 1.93B 83.2B | P/E 2026 * |
7.51x | P/E 2027 * | 6.56x |
|---|---|---|---|---|---|
| Enterprise Value | 65.04B 526M 468M 434M 395M 745M 49.99B 758M 5.21B 2.05B 26.06B 1.98B 1.93B 83.2B | EV / Sales 2026 * |
1.19x | EV / Sales 2027 * | 1.06x |
| Free-Float |
85.91% | Yield 2026 * |
4.13% | Yield 2027 * | 4.73% |
| 1 day | +0.62% | ||
| 1 week | +0.83% | ||
| Current month | -1.22% | ||
| 1 month | -1.95% | ||
| 3 months | -4.89% | ||
| 6 months | +23.98% | ||
| Current year | +42.80% |
| 1 week | 141.6 |  | 146.4 |
| 1 month | 138.5 | | 151.1 |
| Current year | 99.5 | | 158.5 |
| 1 year | 99.5 | | 158.5 |
| 3 years | 64.2 | | 158.5 |
| 5 years | 64.2 | | 236 |
| 10 years | 47.36 | | 255.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Iqbal Ahmed
CEO | Chief Executive Officer | - | 04/03/2024 |
| Director of Finance/CFO | 63 | 01/01/2003 | |
Mohammad Haque
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 19/06/2009 | |
| Director/Board Member | - | 01/02/2010 | |
Iqbal Ahmed
BRD | Director/Board Member | - | 01/01/1985 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.62% | +0.83% | +31.71% | -0.27% | 528M | |
| +0.43% | +6.59% | +53.41% | +103.85% | 1,120B | |
| +0.90% | -2.25% | +33.02% | +62.23% | 616B | |
| +0.71% | +3.24% | +25.81% | +93.86% | 504B | |
| -0.13% | +5.98% | +32.91% | +50.39% | 367B | |
| +0.52% | +0.24% | +73.92% | +40.15% | 360B | |
| -0.95% | +4.70% | +19.51% | +43.00% | 288B | |
| -1.98% | +3.73% | -0.86% | +13.43% | 258B | |
| -0.35% | +4.25% | +46.21% | +50.76% | 234B | |
| -0.75% | +3.32% | +32.53% | +97.21% | 194B | |
| Average | -0.10% | +3.44% | +34.82% | +55.46% | 394.14B | |
| Weighted average by Cap. | +0.13% | +3.83% | +39.18% | +71.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 54.78B 443M 394M 365M 333M 627M 42.1B 638M 4.39B 1.72B 21.95B 1.66B 1.63B 70.08B | 61.27B 496M 441M 408M 372M 702M 47.09B 714M 4.91B 1.93B 24.55B 1.86B 1.82B 78.37B |
| Net income | 8.66B 70.1M 62.38M 57.74M 52.6M 99.2M 6.66B 101M 694M 272M 3.47B 263M 257M 11.08B | 9.92B 80.27M 71.43M 66.12M 60.23M 114M 7.62B 116M 795M 312M 3.97B 301M 295M 12.69B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/10/26 | BDT 145.80 | +0.62% | 236,050 |
| 14/10/26 | BDT 144.90 | +0.35% | 114,202 |
| 13/10/26 | BDT 144.40 | +0.35% | 197,168 |
| 12/10/26 | BDT 143.90 | +0.49% | 278,825 |
| 11/10/26 | BDT 143.20 | -0.97% | 227,494 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BXPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
